secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-049116
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14
--------------------------------------------------------------------------------

- Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.
- Resmetirom PDUFA date March 14, 2024; company anticipates first NASH approval.
- Cash and marketable securities $634.1M at Dec 31, 2023, up from $358.8M at Dec 31, 2022.
- Operating expenses Q4 2023 $117.2M vs $85.3M YoY; full year $380.5M vs $293.6M.
- G&A expenses Q4 2023 $46.5M vs $14.6M YoY due to commercial launch preparation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/0001193125-24-049116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/d743882d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-049116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer